Discriminative stimulus properties of the putative dopamine D3 receptor agonist, (+)-PD 128907: role of presynaptic dopamine D2 autoreceptors

Bristow, Linda J.; Cook, G.P.; Patel, Smita S.; Curtis, Neil R.; Mawer, Ian M.; Kulagowski, Janusz J.

doi:10.1016/s0028-3908(98)00066-5

Cited by 44 publications

(39 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(Zapata et al, 2001). In contrast, evidence from several labs has suggested a lack of selectivity in vivo, at any dose,for both 7-OH-DPAT (Starr and Starr, 1995;Gonzalez and Sibley, 1995) and PD 128907 (Bristow et al, 1998). In Figure 4 Effect of PD 128907 on locomotor activity in nonacclimated, WT mice.…”

Section: D3 Agonist Selectivity In Vivo Is Controversialmentioning

confidence: 91%

7-OH-DPAT and PD 128907 Selectively Activate the D3 Dopamine Receptor in a Novel Environment

Pritchard

Logue

Hayes

et al. 2003

Neuropsychopharmacol

View full text Add to dashboard Cite

The D3 dopamine receptor is expressed primarily in limbic brain areas, and appears to play an inhibitory role in rodent locomotor behavior. Evidence suggests a potential role for the D3 receptor in the pathology of neuropsychiatric disease. Progress in elucidating D3 receptor function has been hampered, however, by a lack of well-characterized, selective ligands and by conflicting information regarding the behavioral phenotype of D3 receptor knockout mice. Here, we describe studies evaluating the behavioral effects of ( 7 )-7-hydroxy-N,N-di-n-propyl-2-aminotetralin (7-OH-DPAT) and PD 128907, two D3 receptor agonists whose in vivo selectivity has been a topic of considerable controversy. We demonstrate that both compounds inhibit locomotion under novel environmental conditions in wild-type (WT) mice, but are without measurable behavioral effect under identical conditions in D3 receptor knockout mice. Additionally, we demonstrate that at low, D3 selective doses, these compounds are without behavioral effect in both WT and D3 receptor knockout mice that have acclimated to the testing environment. These findings suggest that D3 receptor stimulation inhibits novelty-stimulated locomotion, and establish conditions for the use of 7-OH-DPAT and PD 128907 as D3 receptor agonists in vivo. Potential implications of these observations are discussed.

show abstract

Section: D3 Agonist Selectivity In Vivo Is Controversialmentioning

confidence: 91%

7-OH-DPAT and PD 128907 Selectively Activate the D3 Dopamine Receptor in a Novel Environment

Pritchard

Logue

Hayes

et al. 2003

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…In support of the first argument (lack of selectivity) are the findings described in the previous section (i.e., radioligand binding studies vs. in vitro functional assays). In addition to lack of D 3 receptor selectivity under in vitro assay conditions, both 7-OH-DPAT and PD128907 may activate D 2 receptors in vivo in rats as a function of the doses used in different behavioral paradigms [2,19,36,71,73,95,146,159,180,181,203,228,293]. For example, behavioral characterizations of both 7-OH-DPAT and PD128907 up to 10 mg/kg revealed U-shaped dose-response curves for both compounds [2,71,228], suggesting activation of D 3 receptors at low doses and increasing D 2 receptor occupancy at higher doses.…”

Section: Receptor Agonistsmentioning

confidence: 99%

The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence

Heidbreder

Gardner

et al. 2005

Brain Research Reviews

305

249

View full text Add to dashboard Cite

The cDNA for the dopamine D 3 receptor was isolated and characterized in 1990. Subsequent studies have indicated that D 3 receptors, as well as D 3 receptor mRNA, are primarily localized in limbic regions in mammals. This finding led to the postulate that D 3 receptors may be involved in drug dependence and addiction. However, this hypothesis has been difficult to test due to the lack of compounds with high selectivity for central D 3 receptors. The interpretation of results from studies using mixed D 2 /D 3 agonists and/or antagonists is problematic because these agents have low selectivity for D 3 over D 2 receptors and it is likely that their actions are primarily related to D 2 receptor antagonism and possibly interaction with other neurotransmitter receptors. Currently, with the synthesis and characterization of new highly selective D 3 receptor antagonists such as SB-277011-A this difficulty has been surmounted. The purpose of the present article is to review, for the first time, the effects of various putative D 3 receptor selective compounds in animal models of drug dependence and addiction. The results obtained with highly selective D 3 receptor antagonists such as SB-277011-A, SB-414796, and NGB-2904 indicate that central D 3 receptors may play an important role in drug-induced reward, drug-taking, and cue-, drug-, and stressinduced reinstatement of drug-seeking behavior. Provided these results can be extrapolated to human drug addicts, they suggest that selective DA D 3 receptor antagonists may prove effective as potential pharmacotherapeutic agents to manage drug dependence and addiction.

show abstract

“…Quinpirole, at 1 mg/kg i.v., is reported to increase k* for AA in 24 of 29 brain regions having D 2 -like receptors. The increases can be blocked by prior administration of the preferential D 2 -like antagonist ( þ )-butaclamol (Bristow et al, 1998), or enhanced in rat brain regions ipsilateral to a chronic unilateral lesion of the substantia nigra, in proportion to their elevated D 2 -like receptor density (Cory-Slechta et al, 1996;Eilam and Szechtman, 1989;Hayakawa et al, 2001). Quinpirole at the two doses chosen also can provoke orofacial activity and locomotion (Bordi and Meller, 1989;Horvitz et al, 2001;Koene et al, 1993), so we measured these as well.…”

Section: Introductionmentioning

confidence: 99%

Chronic Lithium Chloride Administration to Unanesthetized Rats Attenuates Brain Dopamine D2-Like Receptor-Initiated Signaling Via Arachidonic Acid

Basselin

Chang

Bell

et al. 2005

Neuropsychopharmacol

View full text Add to dashboard Cite

We studied the effect of lithium chloride on dopaminergic neurotransmission via D 2 -like receptors coupled to phospholipase A 2 (PLA 2 ). In unanesthetized rats injected i.v. with radiolabeled arachidonic acid (AA, 20:4 n-6), regional PLA 2 activation was imaged by measuring regional incorporation coefficients k* of AA (brain radioactivity divided by integrated plasma radioactivity) using quantitative autoradiography, following administration of the D 2 -like receptor agonist, quinpirole. In rats fed a control diet, quinpirole at 1 mg/kg i.v. increased k* for AA significantly in 17 regions with high densities of D 2 -like receptors, of 61 regions examined. Increases in k* were found in the prefrontal cortex, frontal cortex, accumbens nucleus, caudate-putamen, substantia nigra, and ventral tegmental area. Quinpirole, 0.25 mg/kg i.v. enhanced k* significantly only in the caudate-putamen. In rats fed LiCl for 6 weeks to produce a therapeutically relevant brain lithium concentration, neither 0.25 mg/kg nor 1 mg/kg quinpirole increased k* significantly in any region. Orofacial movements following quinpirole were modified but not abolished by LiCl feeding. The results suggest that downregulation by lithium of D 2 -like receptor signaling involving PLA 2 and AA may contribute to lithium's therapeutic efficacy in bipolar disorder.

show abstract

Discriminative stimulus properties of the putative dopamine D3 receptor agonist, (+)-PD 128907: role of presynaptic dopamine D2 autoreceptors

Cited by 44 publications

References 29 publications

7-OH-DPAT and PD 128907 Selectively Activate the D3 Dopamine Receptor in a Novel Environment

7-OH-DPAT and PD 128907 Selectively Activate the D3 Dopamine Receptor in a Novel Environment

The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence

Chronic Lithium Chloride Administration to Unanesthetized Rats Attenuates Brain Dopamine D2-Like Receptor-Initiated Signaling Via Arachidonic Acid

Contact Info

Product

Resources

About